Involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test

European Neuropsychopharmacology

Volumn 20, Issue 11, 2010, Pages 793-801

  Zomkowski, Andréa D E ^a   Engel, Daiane ^a   Gabilan, Nelson H ^a   Rodrigues, Ana Lúcia S ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Depression; Escitalopram; Forced swimming test; L arginine; NMDA; Tail suspension test

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 7 NITROINDAZOLE; ARGININE; CYCLIC GMP; ESCITALOPRAM; METHYLENE BLUE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NITRIC OXIDE; SILDENAFIL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; FORCED SWIMMING TEST; LOCOMOTION; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ARGININE; CITALOPRAM; CYCLIC GMP; DEPRESSION; EXPLORATORY BEHAVIOR; FEMALE; HINDLIMB SUSPENSION; MICE; NITRIC OXIDE; RECEPTORS, N-METHYL-D-ASPARTATE; SIGNAL TRANSDUCTION; SWIMMING;

EID: 77957019472     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.07.011     Document Type: Article

References (58)

1. Almeida R.C., Felisbino C.S., López M.G., Rodrigues A.L.S., Gabilan N.H. Evidence for the involvement of l-arginine-nitric oxide cyclic guanosine monophosphate pathway in the antidepressant-like effect of memantine in mice. Behav. Brain Res. 2006, 168:318-322.
2. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 1995, 75:725-748.
3. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000, 47:351-354.
4. Binfaré R.W., Rosa A.O., Lobato K.R., Santos A.R.S., Rodrigues A.L.S. Ascorbic acid administration produces an antidepressant-like effect: evidence for the involvement of monoaminergic neurotransmission. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:530-540.
5. Bourin M., Fiocco A.J., Clenet F. How valuable are animal models in defining antidepressant activity?. Hum Psychopharm. 2001, 16:9-21.
6. Boyer P.A., Skolnick P., Fossom L.H. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridization study. J. Mol. Neurosci. 1998, 10:219-233.
7. Boyce-Rustay J.M., Holmes A. Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic- and antidepressant-like effects in mice. Neuropsychopharmacology 2006, 31:2405-2411.
8. Brocardo P.S., Budni J., Lobato K.R., Kaster M.P., Rodrigues A.L.S. Antidepressant-like effect of folic acid: involvement of NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway. Eur. J. Pharmacol. 2008, 598:37-42.
9. Colonna L., Andersen H.F., Reines E.H. A randomized, double-blind, 24-week study of escitalopram (10mg/day) versus citalopram (20mg/day) in primary care patients with major depressive disorder. Curr. Med. Res. Opin. 2005, 21:1659-1668.
10. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res. Rev. 2000, 32:476-509.
11. Cryan J.F., Mombereau C., Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci. Biobehav. Rev. 2005, 9:571-625.
12. Da Silva G., Matteussi A., Santos A.R.S., Calixto J.B., Rodrigues A.L.S. Evidence for dual effects of nitric oxide in the forced swimming test and in the tail suspension test in mice. NeuroReport 2000, 11:3699-3702.
13. Denninger J.W., Marletta M.A. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim. Biophys. Acta 1999, 1411:334-350.
14. Dhir A., Kulkarni S.K. Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of venlafaxine in mice. Prog. Neuropsychopharmacolo. Biol. Psychiatry 2007, 31:921-925.
15. Ergün Y., Ergün U.G. Prevention of pro-depressant effect of l-arginine in the forced swim test by NG-nitro-l-arginine and [1H-[1, 2, 4]Oxadiazole[4, 3-a]quinoxalin- 1-one]. Eur. J. Pharmacol. 2007, 554:150-154.
16. Eroglu L., Caglayan B. Anxiolytic and antidepressant properties of methylene blue in animal models. Pharmacol. Res. 1997, 36:381-385.
17. Esplugues J.V. NO as a signalling molecule in the nervous system. Brit. J. Pharmacol. 2002, 135:1079-1095.
18. Garcia L.S., Comim C.M., Valvassori S.S., Réus G.Z., Barbosa L.M., Andreazza A.C., Stertz L., Fries G.R., Gavioli E.C., Kapczinski F., Quevedo J. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:140-144.
19. Ghasemi M., Sadeghipour H., Mosleh A., Sadeghipour H.R., Mani A.R., Dehpour A.R. Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test. Eur. Neuropsychopharmacol. 2008, 18:323-332.
20. Ghasemi M., Montaser-Kouhsari L., Shafarodi H., Nezami B.G., Ebrahimi F., Dehpour A.R. NMDA/receptor nitregirc system blockage augments antidepressant-like effects of paroxetine in the mouse forced swimming test. Psychopharmacology 2009, 206:325-333.
21. Ghasemi M., Raza M., Dehpour A. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test. J. Psychopharmacol. 2010, 24:585-594.
22. Harkin A.J., Bruce K.H., Craft B., Paul I.A. Nitric oxide synthase inhibitors have antidepressant-like properties in mice. Acute treatments are active in the forced swim test. Eur. J. Pharmacol. 1999, 372:207-213.
23. Harkin A.J., Connor T.J., Walsh M., St John N., Kelly J.P. Serotonergic mediation of the antidepressant-like effects of nitric oxide synthase inhibitors. Neuropharmacology 2003, 44:616-623.
24. Harkin A., Connor T.J., Burns M.P., Kelly J.P. Nitric oxide inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. Eur. Neuropsychopharmacol. 2004, 14:274-281.
25. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol. Psychiatry 2007, 62:1310-1316.
26. Heiberg I.L., Wegener G., Rosenberg R. Reduction of cGMP and nitric oxide has antidepressant like effects in the forced swimming test in rats. Behav. Brain. Res. 2002, 134:479-484.
27. Hyttel J., Bogeso K.P., Perregaard J., Sánchez C. The pharmacological effect of citalopram resides in the (S)-(+)-enantiomer. J. Neural Transm. Gen. 1992, 88:157-160.
28. Höschl C., Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert. Rev. Neurother. 2008, 8:537-552.
29. Joca S.R., Guimarães F.S. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology 2006, 185:298-305.
30. Kaster M.P., Ferreira P.K., Santos A.R.S., Rodrigues A.L.S. Effect of potassium channel inhibitors in the forced swimming test: possible involvement of l-arginine-nitric oxide-soluble guanylate cyclase pathway. Behav. Brain Res. 2005, 165:204-209.
31. Kaster M.P., Rosa A.O., Santos A.R., Rodrigues A.L. Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int. J. Neuropsychopharmacol. 2005, 8:601-606.
32. Kulkarni S.K., Dhir A. Possible involvement of l-arginine-nitric oxide (NO)-cyclic guanosine monophosphate (cGMP) signaling pathway in the antidepressant-like activity of berberine chloride. Eur. J. Pharmacol. 2007, 569:77-83.
33. Lam R.W., Andersen H.F., Wade A.G. Escitalopram and duloxetine in the treatment of major depressive disorder: a pooled analysis of two trials. Int. Clin. Psychopharmacol. 2008, 23:181-187.
34. Law A.J., Deakin J.F. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 2001, 12:2971-2974.
35. Ledo A., Frade J., Barbosa R.M., Laranjinha J. Nitric oxide in brain: diffusion, targets and concentration dynamics in hippocampal subregions. Mol. Aspects Med. 2004, 25:75-89.
36. Moncada S., Bolaños J.P. Nitric oxide, cell bioenergetics and neurodegeneration. J. Neurochem. 2006, 16:1676-1689.
37. Moore N., Verdoux H., Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int. Clin. Psychopharmacol. 2005, 20:131-137.
38. Nowak G., Ordway G.A., Paul I.A. Alterations in the N-methyl-d-aspartate (NMDA) receptor complex in the frontal cortex of suicide victims. Brain Res. 1995, 675:157-164.
39. Paul I.A., Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann. N. Y. Acad. Sci. 2003, 1003:250-272.
40. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
41. Rogóz Z., Skuza G., Maj J., Danysz W. Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropsychopharmacology 2002, 42:1024-1030.
42. Rogóz Z., Skuza G., Kuśmider M., Wójcikowski J., Kot M., Daniel W.A. Synergistic effect of imipramine and amantadine in the forced swimming test in rats. Behavioral and pharmacokinetic studies. Pol. J. Pharmacol. 2004, 56:179-185.
43. Rosa A.O., Lin J., Calixto J.B., Santos A.R.S., Rodrigues A.L.S. Involvement of NMDA receptors and l-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav. Brain Res. 2003, 144:87-93.
44. Sanacora G., Zarate C.A., Krystal J.H., Manji H.K. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Rev Drug Disc. 2008, 7:426-437.
45. Sánchez C., Bergqvist P.B.F., Brennum L.T., Gupta S., Hogg S., Larsen A., Wiborg O. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology 2003, 167:353-362.
46. Sánchez C., Gruca P., Bien E., Papp M. R-citalopram counteracts the effect of escitalopram in a rat conditioned fear stress model of anxiety. Pharmacol. Biochem. Behav. 2003, 75:903-907.
47. Sánchez C., Bøgesø K.P., Ebert B., Reines E.H., Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology 2004, 174:163-176.
48. Skolnick P. Antidepressants for the new millennium. Eur. J. Pharmacol. 1999, 375:31-40.
49. Steru L., Chermat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
50. Suzuki E., Yagi G., Nakaki T., Kamba S., Asai M. Elevated plasma nitrate levels in depressive states. J. Affect. Disord. 2001, 63:221-224.
51. Szasz B.K., Mike A., Karoly R., Gerevich Z., Illes P., Vizi E.S., Kiss J.P. Direct inhibitory effect of fluoxetine on N-methyl-d-aspartate receptors in the central nervous system. Biol. Psychiatry 2007, 62:1303-1309.
52. Ulak G., Mutlu O., Akar F.Y., Komsuoǧlu F.I., Tanyeri P., Erden B.F. Neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole augment the effects of antidepressants acting via serotonergic system in the forced swimming test in rats. Pharmacol. Biochem. Behav. 2008, 90:563-568.
53. Volke V., Wegener G., Bourin M., Vasar E. Antidepressant- and anxiolytic-like effects of selective neuronal NOS inhibitor 1-(2-trifluoromethylphenyl)-imidazole in mice. Behav. Brain Res. 2003, 140:141-147.
54. Wegener G., Volke V., Harvey B.H., Rosenberg R. Local, but not systemic administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res. 2003, 959:128-134.
55. Wong M.L., Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001, 2:343-351.
56. Yildiz F., Erden B.F., Ulak G., Utkan T., Gacar N. Antidepressant-like effect of 7-nitroindazole in the forced swimming test in rats. Psychopharmacology 2000, 149:41-44.
57. Zarate C.A., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A., Charney D.S., Manji H.K.A. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiatry 2006, 63:856-864.
58. Zomkowski A.D.E., Hammes L., Lin J., Calixto J.B., Santos A.R.S., Rodrigues A.L.S. Agmatine produces antidepressant-like effects in two models of depression in mice. NeuroReport 2002, 13:387-391.